Armata Pharmaceuticals (ARMP) Capital Expenditures (2013 - 2026)

Armata Pharmaceuticals has reported Capital Expenditures for 14 years, with the latest figure at $63000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 36.36% year-over-year to $63000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $506000.0 (down 70.72% YoY) and the FY2025 annual result came in at $542000.0, down 71.15% from the prior year.
• Capital Expenditures climbed to $63000.0 in Q1 2026 per ARMP's latest filing, from $52000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $3.5 million in Q3 2023 and troughed at -$455000.0 in Q4 2022.
• A 5-year average of $755235.3 and a median of $242000.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures slumped 299.56% in 2022, then surged 751.69% in 2023.
• Over 5 years, Capital Expenditures stood at -$455000.0 in 2022, then surged by 627.47% to $2.4 million in 2023, then slumped by 103.21% to -$77000.0 in 2024, then soared by 167.53% to $52000.0 in 2025, then increased by 21.15% to $63000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $63000.0, $52000.0, and $242000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.